Finasteride significantly reduces the risk of prostate cancer.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
November 2022 in “American Journal of Clinical Pathology” TURP specimens should be checked for various tumors, not just common prostate issues.
37 citations
,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
29 citations
,
February 2016 in “Scandinavian journal of urology” Late puberty may slightly lower prostate cancer risk, baldness is not linked to overall risk but less so with aggressive types, ibuprofen use may increase risk, and vitamins show no effect on risk.
12 citations
,
October 2018 in “Aging male/The aging male” Higher BMI and lower testosterone are linked to more aggressive prostate cancer.
4 citations
,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
2 citations
,
July 2006 in “European Urology Supplements” 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
July 2019 in “Journal of the Formosan Medical Association” Melatonin may help with nerve pain, a hepatitis C drug is effective but has side effects, a treatment for mouth sores works but can cause blood issues, ear reconstruction with an implant is safe, HIV transmission from mother to child in Taiwan is now 0% with treatment, certain blood problems are more common in people with a tongue condition, a gene and being overweight are linked to hair loss in some women, a new technique could reduce radiation for lung nodule patients, a hepatitis treatment may lower cancer recurrence after a procedure, and adding extra screening improves tuberculosis detection in patients with lung infections.
Finasteride significantly reduces prostate cancer risk.
January 2005 in “Urologia Journal” 5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.
262 citations
,
May 2017 in “Nanomedicine” New nanofiber technology improves wound healing by supporting cell growth and delivering treatments directly to the wound.
728 citations
,
August 1996 in “The New England Journal of Medicine” Terazosin and finasteride effectively treat BPH, but combining them adds no extra benefit.
581 citations
,
October 1998 in “Journal of The American Academy of Dermatology” Finasteride safely and effectively treats male pattern hair loss, but may cause reversible sexual issues and harm male fetuses.
466 citations
,
August 2004 in “Journal of the American Academy of Dermatology” Rosacea is a skin condition with unclear causes, classified into four subtypes.
408 citations
,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
402 citations
,
August 2011 in “Cancer research” Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
219 citations
,
July 1995 in “PubMed” Keratinocyte growth factor promotes hair growth and reduces hair loss from chemotherapy.
160 citations
,
January 2009 in “Clinical Drug Investigation” HairMax LaserComb® effectively promotes hair growth and stops hair loss in males with androgenetic alopecia, with no serious side effects.
151 citations
,
August 2011 in “The EMBO Journal” The enzyme PA-PLA1α is important for proper hair follicle development.
147 citations
,
April 1990 in “The Journal of Clinical Endocrinology and Metabolism” Finasteride safely lowers DHT levels without affecting testosterone.
139 citations
,
December 2021 in “Journal of Clinical Medicine” Fatigue is the most common symptom in both ongoing symptomatic COVID-19 and post-COVID-19 syndrome.
136 citations
,
April 2013 in “Clinical Cancer Research” The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
109 citations
,
January 1980 in “Science of the total environment” Analyzing trace elements in human hair is complex and needs a standardized method.
100 citations
,
November 1996 in “Molecular Medicine Today” Growth factors and cytokines are important for hair growth and could potentially treat hair loss, but more research is needed to overcome challenges before they can be used in treatments.
93 citations
,
February 2008 in “Atmospheric environment” Ozone reacts more with unwashed hair, producing compounds due to scalp oils, which could lower ozone exposure but increase exposure to reaction products.
84 citations
,
November 2003 in “European journal of endocrinology” Women with androgenic alopecia are more likely to have polycystic ovaries and higher androgen levels, which may indicate PCOS.
81 citations
,
May 2007 in “Fertility and Sterility” Testosterone therapy seems safe for postmenopausal women for a few years, but more research is needed for long-term effects.
57 citations
,
September 2017 in “Journal of controlled release” Nanocarrier-loaded gels improve drug delivery for cancer, skin conditions, and hair loss.
50 citations
,
January 2018 in “Acta physiologica” Working night shifts for four days can lower the body's ability to use insulin, which may increase the risk of type 2 diabetes.